Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EmbectaEMBC -2.97%53 EV-to-EBIT is 5.08 as of Jul. 22, 2026, which is 54% below its 10-year median of 11.09. GuruFocus rates EMBC with a GF Score™ of 53/100 and a GF Value™ of $12.65 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Embecta ranks better than 91.18% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Embecta's Enterprise Value is $1,367 Mil.
Embecta's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $269 Mil. Therefore, Embecta's EV-to-EBIT for today is 5.08.
The historical rank and industry rank for Embecta's EV-to-EBIT or its related term are showing as below:
EMBC'
s EV-to-EBIT Range Over the Past 10 Years
Min: 5.04 Med: 11.09 Max: 18.14
Current: 5.08
During the past 7 years, the highest EV-to-EBIT of Embecta was 18.14. The lowest was 5.04. And the median was 11.09.
EMBC's EV-to-EBIT is ranked better than 91.18% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.28
vs EMBC: 5.08
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Embecta's Enterprise Value for the quarter that ended in Mar. 2026 was $1,697 Mil.
Embecta's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $269 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embecta EV-to-EBIT Related Terms
Embecta EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Embecta's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Embecta's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Embecta's EV-to-EBIT falls into.
Embecta's current Enterprise Value is $1,367 Mil.
Embecta's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $269 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embecta (EMBC) has a EV-to-EBIT of 5.08 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Embecta and its competitors. This is 54% below median its historical median of 11.09. Over the past decade, Embecta's EV-to-EBIT has ranged from 5.04 to 18.14. According to the industry distribution chart, Embecta ranks #41 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 8.8%.
Is Embecta's EV-to-EBIT too high?
Embecta's current EV-to-EBIT of 5.08 is 54% below median its 10-year median of 11.09. Over the past 10 years, this metric has ranged from a low of 5.04 to a high of 18.14. The Medical Devices & Instruments industry median EV-to-EBIT is 18.28. Embecta's value of 5.08 is 72.2% below this industry median. Based on the distribution chart, Embecta ranks #41 out of 465 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embecta has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Embecta's EV-to-EBIT compare to KRMD and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #41 out of 465 companies for EV-to-EBIT. This places Embecta in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.28. Embecta's value of 5.08 is 72.2% below this benchmark. Historically, Embecta's own EV-to-EBIT has ranged from 5.04 to 18.14 over the past decade. While the company's 10-year median is 11.09 vs. the industry median of 18.28, Embecta has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.28, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embecta's current EV-to-EBIT of 5.08 is 72.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Embecta and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embecta's current EV-to-EBIT is 5.08, which is 54% below median its own 10-year median of 11.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Based on GuruFocus' analysis, Embecta (EMBC) is currently considered Possible Value Trap. The stock's GF Value™ is $12.65, compared to a current price of $3.27 — trading 74.2% below its estimated fair value. The current EV-to-EBIT is 5.08, which is 54% below median its 10-year median of 11.09 and 72.2% below the Medical Devices & Instruments industry median of 18.28. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Embecta (EMBC), the current EV-to-EBIT is 5.08 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of $3.27 is trading 74.2% below its estimated GF Value™ of $12.65.
GuruFocus considers Embecta to be Possible Value Trap.
Key valuation signals for EMBC:
EV-to-EBIT: 5.08 (54% below median its 10-year median of 11.09)
GF Value™: $12.65 vs. price of $3.27 (74.2% below fair value)
Industry Position: 72.2% below the Medical Devices & Instruments median (#41 of 465)
No single metric tells the full story. See the EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score
Get the complete analysis for EMBC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMBC has been successfully added to your 
